DCM Advisors’s Exact Sciences EXAS Stock Holding History

DCM Advisors’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,465	Closed	-$425K	–	196
2021 Q4	$425K	Sell	5,465 -1,800	-25%	-$159K	0.13%	150
2021 Q3	$693K	Buy	+7,265	New	+$767K	0.27%	102

Other funds holding EXAS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM Advisors's EXAS Position: Q1 2022 in Review

DCM Advisors sold out of Exact Sciences (EXAS) in Q1 2022, closing a stake of 5,465 shares — an estimated $425K sold.

DCM Advisors first reported a position in EXAS in Q3 2021 and held it in 2 quarters. The position peaked at $693K in Q3 2021. 559 funds tracked by Wall St. Rank hold EXAS as of Q1 2022.

DCM Advisors reported no remaining Exact Sciences position as of Q1 2022 after selling out during the quarter.
DCM Advisors sold 5,465 Exact Sciences shares in Q1 2022, an estimated $425K.
DCM Advisors first reported a position in Exact Sciences in Q3 2021 and held it in 2 quarters.
DCM Advisors's Exact Sciences position peaked at $693K in Q3 2021.
559 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2022.

Based on DCM Advisors's 13F filing for Q1 2022, filed 9 May 2022.